In this study, we demonstrated that Smad3 is essential for TGF-β1-mediated cancer progression, as both genetic deletion and pharmacological inhibition of Smad3 produced a significant inhibition of cancer growth, invasion and metastasis, resulting in a markedly improved survival rate in mouse models of LLC lung cancer and B16F10 melanoma. This evidence concerns the gene SMAD3 and lung carcinoma.